Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Osemitamab by Transcenta for Metastatic Biliary Tract Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
Data Insights
Osemitamab by Transcenta for Metastatic Biliary Tract Cancer: Likelihood of Approval
Osemitamab is under clinical development by Transcenta and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...